Castrate-resistant Prostate Cancer Market is expected to grow at a CAGR of 15.1% during the forecasted period | Evolve Business Intelligence

Key Highlights:
• The global Castrate-resistant Prostate Cancer Market size was valued at USD 13.1 billion in 2023 growing at a CAGR of 15.1% from 2023 to 2033.
• North America dominated the market in 2023
• Asia Pacific is expected to grow at the highest CAGR from 2023 to 2033

As per the study initiated by Evolve Business Intelligence, the global Castrate-resistant Prostate Cancer Market size accounted for USD 13.1 Billion in 2023, growing at a CAGR of 15.1% from 2023 to 2033. Castration-resistant prostate cancer (CRPC) is a form of prostate cancer that no longer responds to hormone therapy, specifically androgen deprivation therapy (ADT). Prostate cancer cells typically rely on male hormones, such as testosterone, to grow and survive. Hormone therapy works by suppressing the production or blocking the action of these hormones, but over time, some cancer cells may adapt and continue to grow despite low levels of testosterone.

Request/Download PDF Sample: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=021801

As the population ages, the incidence of prostate cancer, including castration-resistant forms, is expected to rise. Ongoing research and development efforts have led to the discovery of new treatment options for castration-resistant prostate cancer, driving market growth. The development of novel therapies, such as targeted therapies and immunotherapies, contributes to market expansion. Improved diagnostic tools and techniques enable earlier detection of castration-resistant prostate cancer, leading to increased demand for treatments.

Key Players
Some of the major Castrate-resistant Prostate Cancer Market players holding high market shares include Sanofi; Johnson & Johnson Services, Inc.. These players use partnership and collaboration as a key strategy to gain significant market share to compete with market leaders. Some of the other major market players include Pfizer, Inc.; Astellas Pharma, Inc.; Bayer AG

For More Information: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=021801

Segmental Analysis
Based on treatment type, the Castrate-resistant Prostate Cancer market is segmented into Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, and Others. The largest segment in the Castrate-resistant Prostate Cancer market is Hormone Therapy. This is because hormone therapy is the first-line treatment for CRPC and is effective in delaying disease progression and improving survival. Additionally, hormone therapy is relatively well-tolerated and has a long history of use in CRPC.
Based on the distribution channel, the Castrate-resistant Prostate Cancer market is Hospitals, Clinics, Online Pharmacies, and Others. The largest segment in the Castrate-resistant Prostate Cancer market is Hospitals. This is because hospitals are the primary setting for CRPC diagnosis and treatment. They have the necessary resources and expertise to provide complex care for CRPC patients, including chemotherapy, radiation therapy, and surgery. Additionally, hospitals are often the only providers of certain CRPC treatments, such as chemotherapy and immunotherapy.

Key Region/ Countries Covered
• North America (US, Canada, Mexico)
• Europe (Germany, U.K., France, Italy, Spain, Russia, Nordic Countries, BeNeLux, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Rest of Asia Pacific)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, South Africa, Rest of MEA)
• Latin America (Mexico, Brazil, Argentina, Rest of Latin America)

Evolve Business Intelligence
C-218, 2nd floor, M-Cube
Gujarat 396191
India
Email: sales@evolvebi.com
Website: https://evolvebi.com/

Evolve Business Intelligence is a market research, business intelligence, and advisory firm providing innovative solutions to challenging pain points of a business. Our market research reports include data useful to micro, small, medium, and large-scale enterprises. We provide solutions ranging from mere data collection to business advisory.
Evolve Business Intelligence is built on account of technology advancement providing highly accurate data through our in-house AI-modelled data analysis and forecast tool - EvolveBI. This tool tracks real-time data including, quarter performance, annual performance, and recent developments from Fortune's global 2000 companies.

This release was published on openPR.